Is IMPL or XYLD a better dividend investment in 2026?

IMPL currently yields 5000.00% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: IMPL offers higher current income.

What is the dividend yield difference between IMPL and XYLD?

IMPL has a forward dividend yield of 5000.00% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 4989.02 percentage points.

Home › Compare › IMPL vs XYLD

IMPL vs XYLD: Dividend Comparison 2026

IMPL yields 5000.00% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IMPL wins by $62217131802825.33M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IMPL

● Live price

5000.00%

Share price

$0.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$62217131802825.35M

Annual income

$59,861,980,287,378,210,000.00

Full IMPL calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — IMPL vs XYLD

📍 IMPL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IMPL	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IMPL + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IMPL pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMPL

Annual income on $10K today (after 15% tax)

$425,000.00/yr

After 10yr DRIP, annual income (after tax)

$50,882,683,244,271,480,000.00/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, IMPL beats the other by $50,882,683,244,271,480,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMPL + XYLD for your $10,000?

IMPL: 50%XYLD: 50%

100% XYLD50/50100% IMPL

Portfolio after 10yr

$31108565901412.69M

Annual income

$29,930,990,143,689,105,000.00/yr

Blended yield

96.21%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on IMPL right now

IMPL

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-23.9

Piotroski

4/9

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMPL buys

XYLD buys

No recent congressional trades found for IMPL or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIMPLXYLD

Forward yield	5000.00% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$62217131802825.35M ✓	$25.3K
Annual income after 10y	$59,861,980,287,378,210,000.00 ✓	$3,219.02
Total dividends collected	$62057786341622.61M ✓	$19.6K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: IMPL vs XYLD ($10,000, DRIP)

Year	IMPL Portfolio	IMPL Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$510,700	$500,000.00	$10,818	$1,098.39	+$499.9K → IMPL
2	$24,410,935	$23,864,485.98	$11,738	$1,222.51	+$24.40M → IMPL
3	$1,092,192,501	$1,066,072,800.30	$12,774	$1,364.64	+$1092.18M → IMPL
4	$45,746,366,951	$44,577,720,975.17	$13,944	$1,527.86	+$45746.35M → IMPL
5	$1,793,932,828,410	$1,744,984,215,772.56	$15,270	$1,715.87	+$1793932.81M → IMPL
6	$65,871,973,805,320	$63,952,465,678,921.49	$16,775	$1,933.09	+$65871973.79M → IMPL
7	$2,265,146,887,602,700	$2,194,663,875,631,007.20	$18,490	$2,184.87	+$2265146887.58M → IMPL
8	$72,954,689,148,998,180	$70,530,981,979,263,280.00	$20,450	$2,477.63	+$72954689148.98M → IMPL
9	$2,201,076,182,660,884,700	$2,123,014,665,271,456,500.00	$22,697	$2,819.19	+$2201076182660.86M → IMPL
10	$62,217,131,802,825,350,000	$59,861,980,287,378,210,000.00	$25,280	$3,219.02	+$62217131802825.33M → IMPL

IMPL vs XYLD: Complete Analysis 2026

IMPL — Stock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Full IMPL Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this IMPL vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMPL vs SCHD IMPL vs JEPI IMPL vs O IMPL vs KO IMPL vs MAIN IMPL vs QYLD IMPL vs JEPQ IMPL vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.